Veracyte (VCYT) Stock News

Veracyte (NASDAQ:VCYT) announced its participation in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference. The company's management will engage in a fireside chat on September 9, 2025, at 4:50 p.m. Eastern Time. Investors can access a live audio webcast of the presentation through Veracyte's investor relations website, with the replay remaining available for 90 days following the event.

Veracyte (NASDAQ:VCYT) announced groundbreaking results from the Phase 3 STAMPEDE trial, published in Cell, demonstrating that their Decipher Prostate Genomic Classifier can predict chemotherapy effectiveness in metastatic prostate cancer patients.

The study of 1,523 patients revealed that those with higher Decipher scores showed improved survival benefit from docetaxel treatment (HR 0.64), while those with lower scores did not benefit significantly (HR 0.96). The trial followed patients for a median of 14 years.

Veracyte launched the expanded Decipher test for metastatic prostate cancer in June 2025, addressing an urgent need as prostate cancer causes nearly 400,000 deaths globally and is the second-leading cause of cancer deaths among U.S. men, with 315,000 new diagnoses expected this year.

Veracyte (NASDAQ:VCYT) has completed enrollment for its NIGHTINGALE clinical utility trial, evaluating the Percepta Nasal Swab test for lung cancer detection. The trial has successfully enrolled 2,400 patients across 90+ centers in the United States.

The prospective, randomized, blinded trial will follow patients for up to two years to assess the test's ability to reduce unnecessary procedures for benign nodules and accelerate treatment for cancerous ones. The Percepta Nasal Swab test has demonstrated strong clinical validation results, showing 97% sensitivity with 40% specificity for low-risk nodules and 92% specificity with 57% sensitivity for high-risk nodules.

Veracyte (NASDAQ:VCYT) reported strong Q2 2025 financial results with total revenue growing 14% year-over-year to $130.2 million. Testing revenue increased 14% to $122.3 million, driven by exceptional performance of Decipher tests, which achieved a 28% volume growth. The company recorded a GAAP net loss of $1.0 million, including $20.5 million in one-time impairment charges related to French subsidiary restructuring.

Key highlights include Decipher revenue growth of 24% to $76.3 million and Afirma revenue increase of 5% to $43.4 million. The company generated $33.6 million in operating cash flow and ended the quarter with $320.7 million in cash and equivalents. Following strong performance, Veracyte raised its full-year 2025 testing revenue guidance to $477-483 million and adjusted EBITDA margin guidance to 23.5%.

Veracyte (NASD: VCYT) is set to join the S&P SmallCap 600 index effective prior to market opening on July 29, 2025. The company will replace Triumph Group (NYSE: TGI), which is being acquired by Warburg Pincus LLC and Berkshire Partners LLC.

The index change comes as Triumph Group's acquisition is expected to close soon, pending final conditions. Veracyte will be added to the Health Care sector of the index, while Triumph Group will be removed from the Industrials sector.

Veracyte (NASDAQ:VCYT), a cancer diagnostics company, has scheduled its second quarter 2025 financial results release for August 6, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update.

Investors can access the live webcast through the company's website, and a replay will be available at the investor relations section. Conference call participation requires pre-registration through the provided link.

Veracyte (NASDAQ:VCYT) announced that three research abstracts utilizing their Afirma GRID database will be presented at ENDO 2025, the annual Endocrine Society meeting, taking place July 12-15 in San Francisco.

The presentations will focus on various aspects of thyroid cancer research, including vitamin D signaling expression markers, cell cycle progression scoring for prognosis prediction, and retinoic acid receptor expression in thyroid tumors. All three posters will be presented on Monday, July 14, from 12:00-1:30 p.m. PT at the Moscone Convention Center.

The research demonstrates the capabilities of Veracyte's whole-transcriptome-based Afirma GRID research tool in advancing the understanding of thyroid cancer at the molecular level, supporting the company's mission to enable personalized cancer care.

Veracyte (VCYT) announced the presentation of eight abstracts featuring data from its Decipher Prostate and Bladder genomic classifiers at the upcoming ASCO meeting. Key findings from the STAMPEDE trial showed that metastatic prostate cancer patients with PTEN-inactive gene signatures had a 43% reduced risk of death when adding docetaxel to standard ADT therapy, while PTEN-active patients showed no benefit. The study followed 832 patients for 14 years. Additionally, the SURE-02 Phase 2 study revealed promising results for bladder cancer patients, demonstrating that neoadjuvant Sacituzumab Govitecan plus Pembrolizumab treatment was safe and effective for muscle-invasive bladder cancer (MIBC). The research utilized Veracyte's Decipher GRID platform, showing associations between Luminal subtype and clinical complete response, potentially enabling more personalized treatment approaches.

Veracyte (NASDAQ: VCYT), a cancer diagnostics company, has announced its participation in two upcoming investor conferences in June 2025. The company will present at the William Blair 45th Annual Growth Stock Conference in Chicago on June 3rd at 5:40 p.m. ET, followed by a presentation at the Jefferies Global Healthcare Conference in New York on June 4th at 2:00 p.m. ET.

Live audio webcasts will be accessible through Veracyte's investor relations website, with replays available for 90 days following each presentation.